To purify Japanese encaphalitis virus for vaccine production at semiindustrial scale

42 lots of Japaness encaphalitis virus were purified from viral infected rat brain mixture, for obtaining 28 lots of vaccine products. All lots of vaccine were met WHO standard through local and national laboratory qualification ultracentrifugal 126000 g within 5 hours demonstrated that saturated ammonium sulphate precipitated procedure had removed 26.4% to 32% of protein, then ultricentyrifugal sucrose had removed almost the rest. Protein contents in producted vaccine reached 6.53-61.3%

The efficiency of oral cholera vaccine produced industrial scale

Oral cholera vaccine efficiency was studied with the strains of V. cholerae 01, Cairo 50, V. cholerae 01.569B, V. cholerae 01 Phil 6973, El Tor, as antigene. According to the standards issued by the National Centre of Control of Medical Biopreparation, the samples of vaccine producted at industrial scale in the Company No1 of Vaccines and Biological Preparation belong the National Institute of Hygiene and Epidemiology was satisfied

Chemical composition of oral cholera vaccine 2001-2002

At Cho Ray Hospital – Ho Chi Minh city from Dec 2001 to Dec 2002, 228 heart failure cases (96 males, 130 females, aged 58.4317.45) were studied. Their associated conditions were: 14 with diabetes, 5 brain blood infactus, 5 hyperthyroidies, 19 kidney failures. Among 162 patients with electrolyte disorders, 25 were died, the rate of hyponatremia and hyperkalemia was significantly higher in fatal group than in survival group. Hyponatremia was fatal risk factor and it should pay great attention to treat this condition with hypertonic natrium solution

Chemical composition of oral cholera vaccine 2001-2002

19 lots of oral vaccine producted in the years 2001-2002 at the Company No1 of Vaccines and Biological Preparations were studied. pH=6.9 in the lot 110102, the highest was 7.3 in the lots 050901, 060901 and 091201 (permissible pH=6.8-7.4); thimerosant content from 0.005 g% in the lot 020801 to 0.015 g% in the lots 110102, 120302 and 150502 (permissible content ≤ 0.02 g%); formaldehyde content from 0.005 g% in the lot 060901 to 0.017 g% in the lot 110102 (permissible content ≤ 0.02 g%); total protein content 0.77 g% in the lot 091201 and 1.63 g% in the lot 181002 (permissible content ≤ 2 g%)

On the safety of oral cholerae vaccine produced at Company No1 of Vaccine and Biological Preparation

During 2001-2002 period, 19 lots of oral cholera vaccines were prepared at the Company No1 of Vaccine and Biological Preparation. Weight gain tests were performed on white mice, each test used 20 mices for vaccine sample and 20 mices for control. According to WHO standards and Central National of Control for Biological Preparation standards, cholera vaccine does not cause death for mice, and mean weight of mouse after three days injection is at least equal to that of infection moment and the mean weight gain of the seventh day is higher or equal 60% of control. All 19 lots of vaccine had had high safety